Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01391182 · ClinicalTrials.gov registry record · NA
Epsilon Aminocaproic Acid (EACA) for the Reduction of Blood Loss in Total Hip Arthroplasty (THA)
A NA study, sponsored by Mayo Clinic.
- Completed
- Registry status
- NA
- Development phase
- 60
- Enrollment target
NCT01391182: Completed NA study, sponsored by Mayo Clinic.
NCT01391182 is a NA study that has completed, run by Mayo Clinic. The registered enrollment target is 60 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01391182, a NA study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- NA
- Development phase
- 60 participants
- Enrollment target
Study Summary
You are being asked to take part in this research study because you are scheduled to have total hip replacement (arthroplasty) surgery. The goal of this study is to evaluate the effectiveness of the drug, epsilon Aminocaproic Acid (EACA), in decreasing the need for patients to receive blood after surgery. Currently, EACA is approved by the Federal Drug Administration (FDA) to treat a patient who is bleeding. The investigators plan to use EACA to prevent bleeding during and after surgery; use of this drug as a means of preventing bleeding is not currently approved by the FDA.
Interventions
- OTHER EACA
- OTHER Placebo arm
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2011-07 |
| Est. Completion | 2015-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01391182
The ClinicalTrials.gov registry entry for NCT01391182 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which EACA is the first listed.
NCT01391182 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01391182 about?
NCT01391182 is a clinical study titled "Epsilon Aminocaproic Acid (EACA) for the Reduction of Blood Loss in Total Hip Arthroplasty (THA)". You are being asked to take part in this research study because you are scheduled to have total hip replacement (arthroplasty) surgery. The goal of this study is to evaluate the effectiveness of the drug, epsilon Aminocaproic Acid (EACA), in decreasing the need for patients to receive blood after su...
What is the current status of trial NCT01391182?
This trial is currently completed. It is a NA study. The enrollment target is 60 participants. The study started on 2011-07. Estimated completion is 2015-01.
What interventions are being tested in trial NCT01391182?
The interventions under investigation include: EACA (OTHER), Placebo arm (OTHER).
Who is sponsoring clinical trial NCT01391182?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.